Przerywana stymulacja Theta-Burst w celu poprawy objawów negatywnych i funkcji poznawczych w schizofrenii (ITBS-NKS-2024)
Intermittierende Theta-Burst-Stimulation Zur Verbesserung Von Negativsymptomatik Und Kognition Bei Schizophrenie
The planned randomized, sham-controlled, double-blind, monocentric study aims to evaluate the effectiveness of intermittent Theta-Burst Stimulation (iTBS) on negative symptoms and cognitive deficits in schizophrenia. Both the cerebellar vermis and the left dorsolateral prefrontal cortex will be stimulated successively within the same session.
The goal of this trial is to learn if intermittent theta-burst stimulation (iTBS) of the cerebellum and the left dorsolateral prefrontal cortext (DLPFC) can treat negative symptoms and improve cognition in patients with schizophrenia. The main question it aims to answer is:
Does iTBS of the cerebellum and the left DLPFC improve negative symptoms in patients with schizophrenia? Researchers will compare iTBS to sham stimulation to see if iTBS improves negative symptoms.
Participants will:
- Receive 10 sessions of iTBS over the course of 2 weeks
- Undergo extensive examination before iTBS treatment, immediately after iTBS treatment and 4 weeks after iTBS treatment. The examination includes assessment of negative symptoms; psychometric assessment of cognition, social cognition, depressive symptoms; functional magnetic resonance imaging; assessment of eye movements; blood and saliva sampling; assessment of adverse events and stimulation associated sensations.
The study thus seeks to determine whether iTBS of the fronto-cerebellar network might improve negative symptoms and cognition by altering the network's functional activity. Additionally, it will investigate whether a pro-inflammatory cytokine profile could affect iTBS outcomes and whether inflammatory markers could be affected by iTBS.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Rasmus Schülke, MD (Dr. med.)
- Numer telefonu: +49 511 532 2039
- E-mail: schuelke.rasmus@mh-hannover.de
Lokalizacje studiów
-
-
Lower Saxony
-
Hanover, Lower Saxony, Niemcy, 30625
- Rekrutacyjny
- Hannover Medical School
-
Kontakt:
- Rasmus Schülke, MD (Dr. med.)
- Numer telefonu: +49 511 532 2039
- E-mail: schuelke.rasmus@mh-hannover.de
-
Główny śledczy:
- Rasmus Schülke, MD (Dr. med.)
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Diagnosis of schizophrenia (ICD-10: F20.-)
- Age: 18-65 years
- Ability to give informed consent
- Signed informed consent form
Exclusion Criteria:
- Any electronic implants
- Non-MRI-compatible metal implants (e.g., pacemaker, cochlear implant, insulin pump, metal fragment injuries, work in the metal-processing industry)
- Non-TMS-compatible metal implants (compatible items include: earrings, piercings, dental fillings, crowns, implants)
- Claustrophobia
- Epilepsy
- History of traumatic brain injury within the last 3 months
- History of stroke
- Active central nervous system (CNS) infection
- History of CNS infection within the last 3 months
- Pregnancy
- Current drug, medication, or alcohol abuse
- Simultaneous participation in another clinical trial
- Planned changes in psychopharmacological medication within the next 2 weeks
- Severe physical illnesses that could endanger the patient, affect the examinations or make the MRI scanning cause additional burden
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: iTBS
Active intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex |
Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex |
|
Pozorny komparator: Sham iTBS
Sham intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex |
Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in negative symptoms
Ramy czasowe: From enrollment to the end of iTBS treatment
|
Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points. |
From enrollment to the end of iTBS treatment
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in negative symptoms at 4-week follow-up
Ramy czasowe: From enrollment to follow-up 4 weeks after the end of iTBS treatment
|
Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points. |
From enrollment to follow-up 4 weeks after the end of iTBS treatment
|
|
Speech-gesture rating task
Ramy czasowe: From enrollment to the end of iTBS treatment
|
Accuracy and speed of evaluations in the Speech-Gesture Rating Task. |
From enrollment to the end of iTBS treatment
|
|
Speech-gesture rating task at 4-week follow-up
Ramy czasowe: From enrollment to follow-up 4 weeks after the end of iTBS treatment
|
Accuracy and speed of evaluations in the Speech-Gesture Rating Task at 4-week follow-up. |
From enrollment to follow-up 4 weeks after the end of iTBS treatment
|
|
Eye-Tracking Task
Ramy czasowe: From enrollment to the end of iTBS treatment
|
Changes in eye movements in the Eye-Tracking Task. |
From enrollment to the end of iTBS treatment
|
|
Eye-Tracking Task at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment
|
Changes in eye movements in the Eye-Tracking Task at 4-week follow-up. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
Reading the Mind in the Eyes Test
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment
|
Reading the Mind in the Eyes Test. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
Reading the Mind in the Eyes Test at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment
|
Reading the Mind in the Eyes Test at 4-week follow-up. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
N-Back Test
Ramy czasowe: From enrollment to the end of iTBS treatment
|
Working memory performance in the N-Back Test (sensitivity index). |
From enrollment to the end of iTBS treatment
|
|
N-Back Test at 4-week follow-up
Ramy czasowe: From enrollment to the end of iTBS treatment
|
Working memory performance in the N-Back Test (sensitivity index) 4 weeks after the end of iTBS treatment. |
From enrollment to the end of iTBS treatment
|
|
FMRI: Resting-state functional connectivity
Ramy czasowe: From enrollment to the end of iTBS treatment
|
Changes in resting-state functional connectivity in functional magnetic resonance imaging. Focus on connectivity between cerebellar vermis and DLPFC. |
From enrollment to the end of iTBS treatment
|
|
FMRI: Resting-state functional connectivity at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment
|
Changes in resting-state functional connectivity in functional magnetic resonance imaging. Focus on connectivity between cerebellar vermis and DLPFC. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
FMRI: Task-related functional connectivity
Ramy czasowe: From enrollment to the end of iTBS treatment
|
Changes in task-related functional connectivity in functional magnetic resonance imaging, for the N-Back-task and the speech-gesture rating task. |
From enrollment to the end of iTBS treatment
|
|
FMRI: Task-related functional connectivity at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment
|
Changes in task-related functional connectivity in functional magnetic resonance imaging, for the N-Back-task and the speech-gesture rating task. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
Inflammatory cytokines
Ramy czasowe: From enrollment to the end of iTBS treatment
|
Concentrations of inflammatory cytokines (especially IL-6 and TNF-α) in serum and saliva. |
From enrollment to the end of iTBS treatment
|
|
Inflammatory cytokines at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment
|
Concentrations of inflammatory cytokines (especially IL-6 and TNF-α) in serum and saliva. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
Stimulation-associated perceptions
Ramy czasowe: From the beginning of each iTBS stimulation to after the end of each iTBS stimulation
|
Stimulation-associated perceptions, measured using the TMS Adverse Events and Associated Sensations Questionnaire (TMSensQ, Section IV), after each iTBS session. |
From the beginning of each iTBS stimulation to after the end of each iTBS stimulation
|
|
Therapy dropout rate
Ramy czasowe: From the beginning of iTBS treatment to the end of iTBS treatment
|
Therapy dropout rate (i.e. study termination). |
From the beginning of iTBS treatment to the end of iTBS treatment
|
|
Serious Adverse Events (SAEs)
Ramy czasowe: From the beginning of iTBS treatment to the end of iTBS treatment
|
Serious Adverse Events (SAEs), measured using TMSensQ (Section V). |
From the beginning of iTBS treatment to the end of iTBS treatment
|
|
Self-reported depression: BDI-II
Ramy czasowe: From enrollment to the end of iTBS-treatment
|
Self-reported depression, measured using the Beck Depression Inventory-II (BDI-II). Higher scores correspond to more depressive symptoms. The minimum total score is 0 points, the maximum total score is 63 points. |
From enrollment to the end of iTBS-treatment
|
|
Self-reported depression at 4-week follow-up: BDI-II
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS-treatment
|
Self-reported depression, measured using the Beck Depression Inventory-II (BDI-II). Higher scores correspond to more depressive symptoms. The minimum total score is 0 points, the maximum total score is 63 points. |
From enrollment to 4 weeks after the end of iTBS-treatment
|
|
Self-rated gesture perception and production: BAG
Ramy czasowe: From enrollment to the end of iTBS-treatment
|
Change in self-rated gesture perception and production, measured using the Brief Assessment of Gestures (BAG) questionnaire. Higher BAG scores correspond to greater engagement with or reliance on gestures in communication and indicate stronger tendencies to produce or perceive gestures effectively in different contexts. The minimum total score is 12 points, the maximum total score is 60 points. |
From enrollment to the end of iTBS-treatment
|
|
Self-rated gesture perception and production at 4-week follow-up: BAG
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS-treatment
|
Change in self-rated gesture perception and production, measured using the Brief Assessment of Gestures (BAG) questionnaire. Higher BAG scores correspond to greater engagement with or reliance on gestures in communication and indicate stronger tendencies to produce or perceive gestures effectively in different contexts. The minimum total score is 12 points, the maximum total score is 60 points. |
From enrollment to 4 weeks after the end of iTBS-treatment
|
|
Epigenetic changes of neurotrophic and immunological factors
Ramy czasowe: From enrollment to the end of iTBS treatment
|
Exploratory molecular biological investigations focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, t-PA, S100A10) factors. |
From enrollment to the end of iTBS treatment
|
|
Epigenetic changes of neurotrophic and immunological factors at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment
|
Exploratory molecular biological investigations focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, t-PA, S100A10) factors. |
From enrollment to 4 weeks after the end of iTBS treatment
|
|
Concentrations of markers of neuronal damage
Ramy czasowe: From enrollment to the end of iTBS treatment
|
Concentrations of markers of neuronal damage (e.g., NSE, S100-β) in serum. |
From enrollment to the end of iTBS treatment
|
|
Concentrations of markers of neuronal damage at 4-week follow-up
Ramy czasowe: From enrollment to 4 weeks after the end of iTBS treatment
|
Concentrations of markers of neuronal damage (e.g., NSE, S100-β) in serum. |
From enrollment to 4 weeks after the end of iTBS treatment
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Rasmus Schülke, MD (Dr. med.), Hannover Medical School
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 11473_BO_S_2024
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Whether IPD may be shared has not yet been decided. IPD might not be shared due to data protection laws.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .